dc.rights.license |
Bronze |
|
dc.date.accessioned |
2021-06-03T08:21:31Z |
|
dc.date.available |
2021-06-03T08:21:31Z |
|
dc.date.issued |
2021 |
|
dc.identifier.issn |
0268-3369 |
|
dc.identifier.uri |
www.doi.org/10.1038/s41409-020-01084-x |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/95361 |
|
dc.description |
Bu yayın 06.11.1981 tarihli ve 17506 sayılı Resmî Gazete’de yayımlanan 2547 sayılı Yükseköğretim Kanunu’nun 4/c, 12/c, 42/c ve 42/d maddelerine dayalı 12/12/2019 tarih, 543 sayılı ve 05 numaralı Üniversite Senato Kararı ile hazırlanan Sakarya Üniversitesi Açık Bilim ve Açık Akademik Arşiv Yönergesi gereğince açık akademik arşiv sistemine açık erişim olarak yüklenmiştir. |
|
dc.description.abstract |
In this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients. |
|
dc.language |
English |
|
dc.language.iso |
İngilizce |
|
dc.publisher |
SPRINGERNATURE |
|
dc.relation.isversionof |
10.1038/s41409-020-01084-x |
|
dc.rights |
info:eu-repo/semantics/openAccess |
|
dc.title |
COVID-19 in hematopoietic cell transplant recipients |
|
dc.type |
Article |
|
dc.contributor.authorID |
BERBER, Ilhami/0000-0003-3312-8476 |
|
dc.contributor.authorID |
Basci, Semih/0000-0003-4304-9245 |
|
dc.contributor.authorID |
Erkurt, Mehmet Ali/0000-0002-3285-417X |
|
dc.contributor.authorID |
ULGU, MUSTAFA MAHIR/0000-0003-0825-1851 |
|
dc.contributor.authorID |
BASTURK, ABDULKADIR/0000-0003-1864-0316 |
|
dc.contributor.authorID |
celik, osman/0000-0003-2131-2866 |
|
dc.identifier.volume |
56 |
|
dc.identifier.startpage |
952 |
|
dc.identifier.endpage |
955 |
|
dc.relation.journal |
BONE MARROW TRANSPLANTATION |
|
dc.identifier.issue |
4 |
|
dc.identifier.wos |
WOS:000584556900001 |
|
dc.identifier.doi |
10.1038/s41409-020-01084-x |
|
dc.identifier.eissn |
1476-5365 |
|
dc.contributor.author |
Altuntas, Fevzi |
|
dc.contributor.author |
Ata, Naim |
|
dc.contributor.author |
Yigenoglu, Tugce Nur |
|
dc.contributor.author |
Basci, Semih |
|
dc.contributor.author |
Dal, Mehmet Sinan |
|
dc.contributor.author |
Korkmaz, Serdal |
|
dc.contributor.author |
Namdaroglu, Sinem |
|
dc.contributor.author |
Basturk, Abdulkadir |
|
dc.contributor.author |
Hacibekiroglu, Tuba |
|
dc.contributor.author |
Dogu, Mehmet Hilmi |
|
dc.contributor.author |
Berber, Ilhami |
|
dc.contributor.author |
Dal, Kursat |
|
dc.contributor.author |
Erkurt, Mehmet Ali |
|
dc.contributor.author |
Turgut, Burhan |
|
dc.contributor.author |
Ulgu, Mustafa Mahir |
|
dc.contributor.author |
Celik, Osman |
|
dc.contributor.author |
Akunal, Abdullah |
|
dc.contributor.author |
Birinci, Suayip |
|
dc.relation.publicationcategory |
Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı |
|
dc.identifier.pmıd |
33110186 |
|